Solid 1996 Earnings Growth At Synthelabo
French pharmaceutical group Synthelabo achieved group net profits in1996 of 950.7 million French francs ($168.2 milion), an increase of 19.7%, and earnings per share grew 19.7% to 19.69 francs. Operating profits were ahead 24.8% to 1.52 billion francs.
The firm said that the 24.8% rise in operating profits, after a portion reverted to its joint-venture partner Searle, reflects the growth in sales and an improvement in gross margin related to a strong performance by its strategic products, especially Ambien/Stilnox (zolpidem) in the USA.
Synthelabo posted its sales figures for 1996 in January (Marketletter January 27). Turnover for the year was up 11.3% to 10.4 billion francs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze